Santa Barbara, California, United States, October 13, 2026
Rona Therapeutics has entered into an exclusive global licensing agreement with Roche for an investigational RNA interference (RNAi) therapy targeting activin receptor-like kinase 7 (ALK7) for obesity and metabolic diseases. Announced on October 13, 2026, the agreement combines Rona’s proprietary extrahepatic RNAi delivery platform with Roche’s global drug development and commercialization capabilities. Under the terms, Rona is eligible to receive up to US$100 million in upfront and near-term milestone payments, followed by up to US$1.06 billion in potential development, regulatory and commercial milestone payments, together with tiered royalties on global net sales. The agreement could therefore reach approximately US$1.16 billion in total potential payments, excluding royalties, if the specified milestones are achieved. The collaboration reflects growing pharmaceutical industry interest in innovative obesity treatments that work through mechanisms beyond established incretin-based therapies. Both companies aim to explore the therapeutic potential of targeting fat tissue directly to address obesity and related metabolic conditions.
ALK7-Targeting RNAi Offers a Different Obesity Approach
ALK7, encoded by the ACVR1C gene, belongs to the transforming growth factor-beta receptor superfamily and is predominantly expressed in adipose tissue, where it participates in regulating fat storage, lipolysis and energy balance. Rona’s investigational candidate uses RNA interference technology to silence the genetic instructions responsible for producing the target, with the goal of modifying ALK7 activity in fat cells. According to the companies, this approach has the potential to reduce visceral fat and other ectopic fat deposits while preserving lean body mass. Visceral fat accumulates around internal organs and is associated with metabolic complications, including insulin resistance and cardiovascular risk. The therapeutic rationale is supported by human genetic research linking reduced ALK7 activity with favorable fat distribution and metabolic characteristics. However, genetic associations do not establish that a medicine targeting ALK7 will necessarily produce the same benefits. The candidate remains investigational, and its clinical effectiveness, safety and ability to preserve lean mass will need to be established through appropriate studies. The licensing agreement provides Roche with an opportunity to advance this differentiated biological approach within its broader obesity and metabolic disease research strategy.
Roche Secures Worldwide Rights Under Major License Agreement
Under the agreement, Roche receives exclusive worldwide rights to Rona’s investigational ALK7-targeting RNAi candidate. Rona will receive up to US$100 million in upfront and near-term milestone payments and may qualify for an additional US$1.06 billion based on future development, regulatory and commercial achievements. The company is also eligible for tiered royalties on global net sales if the treatment reaches commercialization. These payments are contingent on specified milestones and should not be interpreted as guaranteed revenue. For Rona, the partnership provides an opportunity to combine its RNAi research and extrahepatic delivery technology with Roche’s experience in clinical development, regulatory strategy and global commercialization. For Roche, the deal expands its potential treatment pipeline in cardiovascular, renal and metabolic diseases, strengthening its efforts to develop new options for people living with obesity. The agreement also illustrates how licensing partnerships can allow biotechnology companies to advance specialized research programs while giving larger pharmaceutical organizations access to emerging therapeutic technologies. Further development plans and clinical milestones will determine how quickly the ALK7 program progresses.
Advertisement
Collaboration Targets Unmet Needs in Metabolic Diseases
Obesity is a chronic, complex disease influenced by biological, genetic and environmental factors. Although incretin-based medicines have expanded treatment options, researchers continue to investigate complementary mechanisms that may improve the quality and durability of weight loss. Unlike therapies that primarily influence appetite and energy intake through incretin pathways, ALK7 inhibition is designed to act directly on adipose tissue biology. This difference creates the possibility of developing a complementary approach that could potentially be used alone or alongside established obesity treatments, subject to future evidence and regulatory approval. Rona Therapeutics focuses on RNAi medicines for cardiometabolic, obesity and degenerative diseases, while Roche continues to expand its research and development activities in metabolic health. The collaboration brings these capabilities together around a target supported by genetic and biological research. Nevertheless, the licensed candidate’s clinical benefits remain unproven, and further research will be necessary to determine its appropriate patient population, dosing, safety profile and potential place in treatment. The agreement marks a significant business development milestone for both companies and highlights continued investment in next-generation obesity therapies.
Source: Rona Therapeutics, Roche press release
